Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

"Triple" Combination of Targeting Methyltransferase, BCL-2 and PD-1 Facilitates Therapeutic Responses in Acute Myeloid Leukemia (AML)

Zhihong Zeng, MD, Shelley Herbrich, PhD, Tianyu Cai, PhD, Antonio Cavazos, MSc, Taylor Manzella, Helen Ma, MS, Vinitha Mary Kuruvilla, MSc, Kala Hayes, Jairo A. Matthews, Courtney D. DiNardo, MD MSCE, Naval Daver, MD, Marina Konopleva, MD PhD

Blood (2020) 136 (Supplement 1): 9–10.

https://doi.org/10.1182/blood-2020-142031

Published: 2020

Journal Articles

AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis

Blood (2020) 136 (Supplement 1): 31–32.

https://doi.org/10.1182/blood-2020-137266

Published: 2020

Journal Articles

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Qi Zhang, PhD, Alessia Lodi, PhD, Shannon Renee Sweeney, PhD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Antonio Cavazos, Helen Ma, MS, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Stefano Tiziani, PhD, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3927.

https://doi.org/10.1182/blood-2019-124494

Published: 2019

Journal Articles

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Qi Zhang, PhD, Sajid Khan, PhD, Xuan Zhang, Vinitha Mary Kuruvilla, MSc, Sanaz Ghotbaldini, Julia Wells, PhD, Natalia Baran, PhDMD, Tianyu Cai, PhD, Lina Han, PhD, Adolfo Ferrando, MD, PhD, Yong-Mi Kim, MD MPH, PhD, Guangrong Zheng, Daohong Zhou, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 3870.

https://doi.org/10.1182/blood-2019-124744

Published: 2019

Journal Articles

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Blood (2019) 134 (Supplement_1): 2659.

https://doi.org/10.1182/blood-2019-126869

Published: 2019

Journal Articles

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, MSc, Xiaoyu Lin, Tamar Uziel, PhD, Xin Lu, Lu Zhang, Xiaoli Huang, Qi Zhang, PhD, Antonio Cavazos, Lina Han, PhD, Yu Shen, Marina Y Konopleva, MD PhD

Blood (2019) 134 (Supplement_1): 1369.

https://doi.org/10.1182/blood-2019-128618

Published: 2019

Journal Articles

Contribution of Amino Acid Metabolism to Hematologic Malignancies

Marina Y. Konopleva, MD PhD, Philip L Lorenzi, PhD, Sanaz Ghotbaldini, Yoko Tabe, MD PhD, Tianyu Cai, PhD, Stefano Tiziani, PhD

Blood (2018) 132 (Supplement 1): SCI-10.

https://doi.org/10.1182/blood-2018-99-109469

Published: 2018

Journal Articles

Transcriptomic Microarray Profile Analysis between Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and TET2 -Mutated Acute Myeloid Leukemia (AML)

Hannah Beird, PhD, Maliha Khan, Feng Wang, PhD, Mansour Alfayez, MD, Tianyu Cai, PhD, Li Zhao, PhD, Andy Futreal, PhD, Marina Y. Konopleva, MD PhD, Naveen Pemmaraju, MD

Blood (2018) 132 (Supplement 1): 3899.

https://doi.org/10.1182/blood-2018-99-118674

Published: 2018

Journal Articles

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Qi Zhang, PhD, Tianyu Cai, PhD, Lina Han, PhD, Vinitha Mary Kuruvilla, Sharlene Adams, PhD, Sloss M Callum, Karine Harutyunyan, PhD, Andrew A. Lane, MD PhD, Yelena Kovtun, PhD, Naval G. Daver, MD, Naveen Pemmaraju, MD, Patrick Zweider McKay, MD PhD, Marina Y. Konopleva, MD PhD

Blood (2018) 132 (Supplement 1): 3956.

https://doi.org/10.1182/blood-2018-99-116771

Published: 2018

Journal Articles

Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability

Tianyu Cai, PhD, Vinitha Mary Kuruvilla, Tamar Uziel, PhD, Qi Zhang, PhD, Lina Han, PhD, Antonio Cavazos, MSc, Yu Shen, Marina Y. Konopleva, MD PhD, Xiaoyu Lin, Xin Lu, Lu Zhang

Blood (2018) 132 (Supplement 1): 1439.

https://doi.org/10.1182/blood-2018-99-116912

Published: 2018

Journal Articles

Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells

Christopher Peter Mill, PhD BA, Tianyu Cai, PhD, Warren Fiskus, BSc,PhD, Gautam Borthakur, MD, Steven M. Kornblau, MD, Tapan M. Kadia, MD, Courtney D. DiNardo, MDMSc, Agnieszka J Nowak, Dyana T. Saenz, PhD, David N Saenz, Baohua Sun, MD PhD, Thurika Ganesh, Wendy Jin, Vaishnavi Rao, Joseph David Khoury, MD, Yu Shen, Marina Y. Konopleva, MD PhD, Kapil N. Bhalla, MD

Blood (2018) 132 (Supplement 1): 1351.

https://doi.org/10.1182/blood-2018-99-113976

Published: 2018

Journal Articles

Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML

Antonio Cavazos, MSc, Helen Ma, MS, Lina Han, PhD, Tianyu Cai, PhD, Qi Zhang, PhD MD, Karine Harutyunyan, PhD, Natalia Baran, PhD MD, Weiguo Zhang, MD PhD, Naval Daver, MD, Michael Andreeff, MD PhD, Amir Ashoorzadeth, PhD, Robert Anderson, MSc, PhD FNZIC, CChem, FRSC, Adam Patterson, PhD, Jeffrey B Smaill, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1342.

https://doi.org/10.1182/blood.V130.Suppl_1.1342.1342

Published: 2017

Journal Articles

BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models

Qi Zhang, PhD MD, Lina Han, PhD, Tianyu Cai, PhD, Vinitha Mary Kuruvilla, Antonio Cavazos, MSc, Helen Ma, MS, Venkata Lokesh Battula, PhD, Natalia Baran, PhD MD, Karine Harutyunyan, PhD, Michael Andreeff, MD PhD, Yoko Tabe, MD PhD, Joseph R Marszalek, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 1362.

https://doi.org/10.1182/blood.V130.Suppl_1.1362.1362

Published: 2017

Journal Articles

Pre-Clinical Activity of Allogeneic Anti-CD22 CAR-T Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Julia Wells, PhD, Tianyu Cai, PhD, Cécile Schiffer-Manniou, PhD, Stéphanie Filipe, PhD, Agnès Gouble, PhD, Roman Galetto, PhD, Nitin Jain, MD, Elias J. Jabbour, MD, Julianne Smith, PhD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 808.

https://doi.org/10.1182/blood.V130.Suppl_1.808.808

Published: 2017

Journal Articles

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MSc, Lina Han, PhD, Qi Zhang, PhD MD, Vinitha Mary Kuruvilla, Sergej Naumovich Konoplev, MD PhD, Sattva S. Neelapu, MD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD

Blood (2017) 130 (Supplement 1): 2625.

https://doi.org/10.1182/blood.V130.Suppl_1.2625.2625

Published: 2017

Journal Articles

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Tianyu Cai, PhD, Philip L Lorenzi, PhD, Dinesh Rakheja, MD, Michael A Pontikos, Alessia Lodi, Lina Han, MD PhD, Qi Zhang, MD PhD, Helen Ma, MS, Mohamed Rahmani, PhD, Tushar Damodar Bhagat, PhD, Thomas D Horvath, PhD, Courtney D. DiNardo, MD MSCE, Steven Grant, MD, Stefano Tiziani, PhD, Amit Verma, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4064.

https://doi.org/10.1182/blood.V128.22.4064.4064

Published: 2016

Journal Articles

Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Tianyu Cai, PhD, Roman Galetto, PhD, Agnès Gouble, PhD, Julianne Smith, PhD, Antonio Cavazos, MS, Sergej Konoplev, MD PhD, Andrew A. Lane, MD PhD, Monica L. Guzman, PhD, Hagop M. Kantarjian, MD, Naveen Pemmaraju, MD, Marina Konopleva, MD PhD

Blood (2016) 128 (22): 4039.

https://doi.org/10.1182/blood.V128.22.4039.4039

Published: 2016

Journal Articles

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax

Joan Montero, PhD, Jason Stephansky, BS, Tianyu Cai, PhD, Gabriel K. Griffin, MD, Katsuhiro Togami, MD PhD, Lucia Cabal-Hierro, PhD, Nicole R. LeBoeuf, MD, Leah Hogdal, PhD, Ilene Galinsky, MSN, ANPc, Jon C. Aster, MD PhD, Matthew S. Davids, Naveen Pemmaraju, MD, Richard M. Stone, MD, Marina Konopleva, MD PhD, Anthony Letai, MD PhD, Andrew A. Lane, MD PhD

Blood (2016) 128 (22): 4045.

https://doi.org/10.1182/blood.V128.22.4045.4045

Published: 2016

NARROW

"Triple" Combination of Targeting Methyltransferase, BCL-2 and PD-1 Facilitates Therapeutic Responses in Acute Myeloid Leukemia (AML)

AZA + Glutaminase Inhibition with Telaglenastat (CB-839) for Advanced MDS: An Updated Interim Analysis

Inhibiting Mitochondria Function By Bcl-2 Inhibitor Venetoclax and Complex I Inhibitor Iacs-010759 Eliminate Leukemia Cells in Pre-Clinical AML Models

Targeting BCL-XL By Protac DT2216 Effectively Eliminates Leukemia Cells in T-ALL Pre-Clinical Models

Efficacy Proof of Concept for Allogeneic CD123 Targeting CAR T-Cells Against Primary Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): Efficient Control of Tumor Progression in PDX Model and Potential Loss of CD123 Expression in Relapsed Disease

Selective Targeting BET Family Bdii Bromodomain with Abbv-744 and BCL-2 with Venetoclax (ABT-199) Is Synergistic in Primary Acute Myeloid Leukemia Models

Contribution of Amino Acid Metabolism to Hematologic Malignancies

Transcriptomic Microarray Profile Analysis between Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) and TET2 -Mutated Acute Myeloid Leukemia (AML)

Pre-Clinical Efficacy of CD123-Targeting Antibody-Drug Conjugate IMGN632 in Blastic Plasmacytoid Dentritic Cell Neoplasm (BPDCN) Models

Targeting the Second Bromodomain (BDII) of BET Family with Abbv-744 Results in Robust Anti-Leukemia Activity in AML Models with Excellent In Vivo Tolerability

Mechanisms Underlying Superior Efficacy of Co-Targeting BET Proteins and Anti-Apoptotic BCL2 or MCL1 Protein Against AML Blast Progenitor Cells

Pre-Clinical Activity of SN37169, a Novel Hypoxia-Activated FLT3 Inhibitor Prodrug in FLT3-Mutated AML

BCL-2 Antagonist ABT-199 Combined with Complex I Inhibitor IACS-010759 Blocks Mitochondrial Respiration and Facilitates Anti-Leukemia Efficacy in Pre-Clinical AML Models

Pre-Clinical Activity of Allogeneic Anti-CD22 CAR-T Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia

Pre-Clinical Studies of Allogeneic Anti-CD123 CAR T-Cells for the Therapy of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Gls Inhibitor CB-839 Modulates Cellular Metabolism in AML and Potently Suppresses AML Cell Growth When Combined with 5-Azacitidine

Pre-Clinical Studies of Anti-CD123 CAR-T Cells for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Is Highly BCL-2 Dependent and Sensitive to Venetoclax

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only